Plus Therapeutics Stock Analysis
| PSTV Stock | USD 1.63 0.03 1.81% |
Plus Therapeutics is undervalued with Real Value of 5.56 and Target Price of 17.5. The main objective of Plus Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Plus Therapeutics is worth, separate from its market price. There are two main types of Plus Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Plus Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Plus Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Plus Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Plus Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Plus Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Plus Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Plus |
Plus Stock Analysis Notes
The company recorded a loss per share of 4.24. Plus Therapeutics last dividend was issued on the 6th of August 2019. The entity had 1:15 split on the 1st of May 2023. Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. Plus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. To find out more about Plus Therapeutics contact Marc MD at 737 255 7194 or learn more at https://plustherapeutics.com.Plus Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Plus Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Plus Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Plus Therapeutics generated a negative expected return over the last 90 days | |
| Plus Therapeutics may become a speculative penny stock | |
| Plus Therapeutics has high historical volatility and very poor performance | |
| Plus Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4.91 M. Net Loss for the year was (13.32 M) with loss before overhead, payroll, taxes, and interest of (9.47 M). | |
| Plus Therapeutics currently holds about 20.27 M in cash with (12.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Plus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive 3M From US Department of Defense |
Plus Therapeutics Upcoming and Recent Events
Earnings reports are used by Plus Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Plus Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 18th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Plus Largest EPS Surprises
Earnings surprises can significantly impact Plus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-10-21 | 2021-09-30 | -0.24 | -0.28 | -0.04 | 16 | ||
2023-02-23 | 2022-12-31 | -0.12 | -0.22 | -0.1 | 83 | ||
2023-10-31 | 2023-09-30 | -1.12 | -1.0 | 0.12 | 10 |
Plus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Plus Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Plus Therapeutics backward and forwards among themselves. Plus Therapeutics' institutional investor refers to the entity that pools money to purchase Plus Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jpmorgan Chase & Co | 2023-09-30 | 2.0 | Group One Trading, Lp | 2023-09-30 | 1.0 | Renaissance Technologies Corp | 2023-12-31 | 33 K | Geode Capital Management, Llc | 2023-09-30 | 26.5 K | Millennium Management Llc | 2023-09-30 | 19.7 K | Vanguard Group Inc | 2023-09-30 | 16.2 K | Hrt Financial Llc | 2023-09-30 | 11.2 K | Blackrock Inc | 2023-12-31 | 7 K | Ubs Group Ag | 2023-09-30 | 5.1 K | Tower Research Capital Llc | 2023-09-30 | 1.5 K | Citigroup Inc | 2023-09-30 | 579 |
Plus Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.23 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Plus Therapeutics's market, we take the total number of its shares issued and multiply it by Plus Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Plus Profitablity
Plus Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Plus Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Plus Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Plus Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Plus Therapeutics' profitability requires more research than a typical breakdown of Plus Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (2.71) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.94) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.94. | Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.21) | (1.27) | |
| Return On Capital Employed | (20.15) | (19.15) | |
| Return On Assets | (1.17) | (1.23) | |
| Return On Equity | 9.88 | 10.37 |
Management Efficiency
Plus Therapeutics has return on total asset (ROA) of (0.4723) % which means that it has lost $0.4723 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.225) %, meaning that it created substantial loss on money invested by shareholders. Plus Therapeutics' management efficiency ratios could be used to measure how well Plus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 10.37 in 2024, whereas Return On Tangible Assets are likely to drop (1.27) in 2024. Total Current Assets is likely to climb to about 17.1 M in 2024, whereas Total Assets are likely to drop slightly above 10.8 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.43) | (0.41) | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | (0.56) | (0.59) | |
| Enterprise Value Over EBITDA | (0.09) | (0.09) | |
| Price Book Value Ratio | (4.08) | (3.87) | |
| Enterprise Value Multiple | (0.09) | (0.09) | |
| Price Fair Value | (4.08) | (3.87) | |
| Enterprise Value | 1.3 M | 1.2 M |
The analysis of Plus Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Plus Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Plus Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.558 |
Technical Drivers
As of the 24th of April, Plus Therapeutics holds the Coefficient Of Variation of (1,859), variance of 19.47, and Risk Adjusted Performance of (0.02). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Plus Therapeutics, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to interpolate and analyze data for thirteen technical drivers for Plus Therapeutics, which can be compared to its competitors. Please check Plus Therapeutics market risk adjusted performance and treynor ratio to decide if Plus Therapeutics is priced some-what accurately, providing market reflects its current price of 1.63 per share. Please also confirm Plus Therapeutics jensen alpha, which is currently at (0.29) to check out the company can sustain itself at a future point.Plus Therapeutics Price Movement Analysis
The output start index for this execution was seven with a total number of output elements of fifty-four. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Plus Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Plus Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Plus Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Plus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Plus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Plus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Petersen Greg over two weeks ago Acquisition by Petersen Greg of 10000 shares of Plus Therapeutics at 2.52 subject to Rule 16b-3 | ||
Andrew Sims over a month ago Acquisition by Andrew Sims of 18933 shares of Plus Therapeutics subject to Rule 16b-3 | ||
Andrew Sims over three months ago Purchase by Andrew Sims of 1000 shares of Plus Therapeutics | ||
Andrew Sims over a year ago Acquisition by Andrew Sims of 104404 shares of Plus Therapeutics subject to Rule 16b-3 |
Plus Therapeutics Predictive Daily Indicators
Plus Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Plus Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Plus Therapeutics Forecast Models
Plus Therapeutics' time-series forecasting models are one of many Plus Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Plus Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Plus Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Plus Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Plus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Plus Therapeutics. By using and applying Plus Stock analysis, traders can create a robust methodology for identifying Plus entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (2.71) | (2.85) | |
| Operating Profit Margin | (3.12) | (3.27) | |
| Net Loss | (2.71) | (2.85) | |
| Gross Profit Margin | 0.85 | 0.89 |
Current Plus Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Plus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Plus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 17.5 | Strong Buy | 3 | Odds |
Most Plus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Plus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Plus Therapeutics, talking to its executives and customers, or listening to Plus conference calls.
Plus Stock Analysis Indicators
Plus Therapeutics stock analysis indicators help investors evaluate how Plus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Plus Therapeutics shares will generate the highest return on investment. By understating and applying Plus Therapeutics stock analysis, traders can identify Plus Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 18.1 M | |
| Common Stock Shares Outstanding | 3.1 M | |
| Total Stockholder Equity | -1.3 M | |
| Property Plant And Equipment Net | 1.1 M | |
| Cash And Short Term Investments | 8.6 M | |
| Cash | 8.6 M | |
| Accounts Payable | 4.8 M | |
| Net Debt | -4.4 M | |
| 50 Day M A | 1.8578 | |
| Total Current Liabilities | 10.7 M | |
| Other Operating Expenses | 18.2 M | |
| Non Current Assets Total | 1.6 M | |
| Non Currrent Assets Other | 32 K | |
| Stock Based Compensation | 569 K |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Plus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Plus Stock analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Stocks Directory Find actively traded stocks across global markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Plus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Plus Therapeutics. If investors know Plus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Plus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.24) | Revenue Per Share 1.564 | Quarterly Revenue Growth 7.695 | Return On Assets (0.47) | Return On Equity (5.22) |
The market value of Plus Therapeutics is measured differently than its book value, which is the value of Plus that is recorded on the company's balance sheet. Investors also form their own opinion of Plus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Plus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Plus Therapeutics' market value can be influenced by many factors that don't directly affect Plus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Plus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Plus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Plus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.